Dongkook wins Korean patent for sustained release formulations of octretide

Published: 2008-03-21 06:57:00

Updated: 2008-03-21 06:57:00

Dongkook Pharm said on March 18 it won Korean patent for octreotide in sustained release form and its manufacturing method, following its development of octreotide injection last year.

Octreotide (brand name Sandostatin, Novartis Inc.) is an octapeptide hat mimics natural somatostatin pharmaco...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK